Covid-19 Treatment, from Dr. Abraham

It is my mission to help people achieve optimal health and wellness. Due to the gravity of the pandemic situation, I have decided to make the COVID-19 Low Dose Immunotherapy (LDI) treatment available to anyone suffering from COVID-19 symptoms. As this is a medical treatment with risks, you are required to book a telehealth appointment with our office staff, but I will offer the LDI treatment itself free of charge. In the spirit of helping fellow humans, I only ask that you make a donation, in any amount, to a charity directly supporting people impacted by COVID-19, prior to treatment, or afterward to receive a refund on your treatment (links to possible local charities are listed below). Due to the considerable fear and skepticism surrounding COVID-19 and treatments, and for those that don’t know me well or understand my work, I hope this offering will demonstrate my passion to help and serve my fellow humans, and that I am in no way looking to profit off of the suffering and fear that surrounds this pandemic.

It is necessary to clarify that the LDI is not a vaccine nor is it a “cure” for COVID-19 and is only a treatment for symptomatic people suspected of exposure to COVID-19. From the beginning of this pandemic, it was clear to me that this virus did not behave like an infection, but rather more like an “allergy” where the symptoms were caused by the body’s widespread inflammatory response. This inflammatory response is “turned on” in response to a protein that the body perceives as foreign, which is the reason for food and environmental allergies. My hypothesis was that the body was actually responding to the COVID-19 proteins (viruses are not living organisms and are not dangerous to humans by themselves) and if we could tell the immune system to “tolerate” this protein, then we could stop the inflammatory response. 

I have been successfully using LDI with hundreds of patients for five years in my clinic to promote “immune tolerance” to proteins that trigger allergies, autoimmune conditions, and inflammation. I decided to try this technique for COVID-19 in the spring of 2020 with a mixture of coronavirus proteins from old strains of the virus. The outcome was complete resolution of symptoms in my first patient. As I continued treating several patients over the summer, I had more success with both acute and chronic symptoms of COVID-19. In the last several weeks I have treated more acute cases and was thoroughly convinced that this treatment was both low-risk and effective. Because of this, I feel ethically obligated to share my findings with the general public. However, like all LDI treatments, this has not been FDA approved so it is your choice whether you feel that is necessary for you to try treatment.

Charities:

Interview with Dr. Peter Abraham and Dr. Ty Vincent regarding the Coronavirus and LDI

Low Dose Immunotherapy (LDI)

What is LDI?

Low Dose Immunotherapy (LDI) is a treatment for increasing immune “tolerance” of an overactive immune system. Allergy and autoimmunity represent an alteration or overactivation of appropriate immune tolerance. LDI retrains the immune system for specific antigens, thereby decreasing overactive immune response and decreasing symptoms.

This type of immunotherapy was discovered in Great Britain in the 1970s and called “Enzyme Potentiated Desensitization” (EPD). The technique utilized very small concentrations of antigens along with an enzyme, beta glucuronidase, which helps educate the T cells involved in the immune response. This treatment was brought to the US, but in the early 1990s the FDA stopped the importation of EPD. At this point, Dr. Shrader reproduced the mixtures of EPD and called them LDA. LDA originally used antigens causing certain allergies and the technique was later expanded by Dr. Vincent to treat various autoimmune conditions using a variety of different antigens, called LDI.

LDI for Autoimmune Diseases
Autoimmune diseases and conditions that involve an overactive immune system (like allergies) can be treated with LDI. It is now understood that many autoimmune diseases are “triggered” by an initial infection. Sometimes, when the immune system recognizes the infection and mounts an attack, through an antibody-mediated immune response, there is a cross reactivity with the body’s own tissue. This process is called “molecular mimicry.” A good example of this is Rheumatic Fever, where damage to the heart can occur after the Streptococcus infection is treated. Often there can be more than one trigger for a disease process.

The key is recognizing the difference between an “infection” and an “immune reaction.” Infections involve an organism in a place where it doesn’t belong and antimicrobial therapy is curative, such as pneumonia, cellulitis, endocarditis, etc. An “immune reaction” is an inflammatory response to an organism that is either a normal organism in the human body, or is not improved with antimicrobial therapy. Chronic Lyme disease is another example of an “immune-mediated” process rather than an “infection.” Many people without Lyme Disease symptoms harbor the bacteria that causes Lyme Disease. Symptoms often do not resolve with antibiotic treatment in Chronic Lyme Disease. Symptoms often return after treatment with antibiotics.

What conditions respond well to LDI?

  • Food allergies/sensitivities, environmental allergens, chemical sensitivities, mold sensitivity
  • Eczema, acne, rashes
  • Chronic Fatigue
  • Crohn’s disease, Ulcerative Colitis, IBS
  • Yeast sensitivity
  • Endometriosis
  • Chronic Lyme Disease
  • Rheumatoid Arthritis, Ankylosing Spondylitis, generalized joint pain
  • Fibromyalgia
  • Herpes outbreaks
  • Chronic Sinusitis

What is the procedure for LDI?
Patients will first undergo a history and physical to determine if LDI or LDA are appropriate therapeutic techniques. Often lab work will be done prior to LDI or LDA therapy to help guide therapy. LDA and LDI doses are given by administering a small drop (less than 1 ml) of the enzyme and antigen mixture under the tongue. Doses are typically repeated every 7–8 weeks, but “booster” doses can be given as soon as 1–2 weeks, based on response to the first dose. The key to LDI is finding the right concentration that the immune system responds to. Concentrations range from 4c up to 20c, or more, if needed. “1c” refers to a 100:1 dilution, and each successive number is another 100:1 dilution.

Because there can be multiple different antigens that trigger the patients’ symptoms, multiple antigens may need to be given before symptoms fully improve. Once we find the antigen or antigens that alleviate symptoms, the antigens can be combined and given together.

What can I expect after LDI treatment?
There are three things that can happen after a dose.

  1. If the dose is too weak, there will be no change in symptoms. We can then proceed with the next stronger concentration in 1–2 weeks.
  2. If the dose is too strong, there will be a flare in symptoms. Flares usually occur in the first 72 hours and usually last a day or two, but can last up to several weeks. A flare is not necessarily a bad thing, because we know we have chosen the right antigen. If we get a flare, we must wait 7–8 weeks for the immune system to “reset.”
  3. If the dose is almost strong enough, there will be a temporary improvement in symptoms, but not lasting the full goal of 7 weeks or more. If this is the case, we know we are close to the right strength, but need to give a slightly stronger dose. We can then give a “booster” dose in 2 weeks.

Once the correct dose is found, doses are given every 7–8 weeks, sometimes with “booster” doses, as needed. Often, patients see longer and longer improvements in symptoms and can space doses out longer than 7–8 weeks, and sometimes are able to stop completely.

For more information, click below to download the LDI Patient Handout pdf:

LDI Patient Handout